Long-term outcomes of imatinib treatment for chronic myeloid leukemia.

BACKGROUND Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses on the basis of more than 10 years of follow-up in patients with CML who were treated with imatinib as initial therapy. METHO...

ver descrição completa

Detalhes bibliográficos
Autores: Hochhaus, Andreas, Larson, Richard A., Guilhot, François, Radich, Jerald P., Branford, Susan, Hughes, Timothy P., Baccarani, Michele, Deininger, Michael W., Cervantes Requena, F., Fujihara, Satoko, Ortmann, Christine E., Menssen, Hans D., Kantarjian, Hagop M., O'Brien, Stephen G., Druker, Brian J.
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2017
País:España
Recursos:Universidad de Barcelona
Repositório:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/108813
Acesso em linha:https://hdl.handle.net/2445/108813
Access Level:Acceso aberto
Palavra-chave:Leucèmia mieloide
Inhibidors enzimàtics
Hematologia
Myeloid leukemia
Enzyme inhibitors
Hematology
id ES_e2fc25866345c6efed7df5350ee04ef6
oai_identifier_str oai:diposit.ub.edu:2445/108813
network_acronym_str ES
network_name_str España
repository_id_str
spelling Long-term outcomes of imatinib treatment for chronic myeloid leukemia.Hochhaus, AndreasLarson, Richard A.Guilhot, FrançoisRadich, Jerald P.Branford, SusanHughes, Timothy P.Baccarani, MicheleDeininger, Michael W.Cervantes Requena, F.Fujihara, SatokoOrtmann, Christine E.Menssen, Hans D.Kantarjian, Hagop M.O'Brien, Stephen G.Druker, Brian J.Leucèmia mieloideInhibidors enzimàticsHematologiaMyeloid leukemiaEnzyme inhibitorsHematologyBACKGROUND Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses on the basis of more than 10 years of follow-up in patients with CML who were treated with imatinib as initial therapy. METHODS In this open-label, multicenter trial with crossover design, we randomly assigned patients with newly diagnosed CML in the chronic phase to receive either imatinib or interferon alfa plus cytarabine. Long-term analyses included overall survival, response to treatment, and serious adverse events. RESULTS The median follow-up was 10.9 years. Given the high rate of crossover among patients who had been randomly assigned to receive interferon alfa plus cytarabine (65.6%) and the short duration of therapy before crossover in these patients (median, 0.8 years), the current analyses focused on patients who had been randomly assigned to receive imatinib. Among the patients in the imatinib group, the estimated overall survival rate at 10 years was 83.3%. Approximately half the patients (48.3%) who had been randomly assigned to imatinib completed study treatment with imatinib, and 82.8% had a complete cytogenetic response. Serious adverse events that were considered by the investigators to be related to imatinib were uncommon and most frequently occurred during the first year of treatment. CONCLUSIONS Almost 11 years of follow-up showed that the efficacy of imatinib persisted over time and that long-term administration of imatinib was not associated with unacceptable cumulative or late toxic effects. (Funded by Novartis Pharmaceuticals; IRIS ClinicalTrials.gov numbers, NCT00006343 and NCT00333840.)Massachusetts Medical Society2017info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/108813Articles publicats en revistes (Medicina)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.1056/NEJMoa1609324New England Journal of Medicine, 2017, vol. 376, num. 10, p. 917-927https://doi.org/10.1056/NEJMoa1609324(c) Massachusetts Medical Society, 2017info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1088132026-05-27T06:46:51Z
dc.title.none.fl_str_mv Long-term outcomes of imatinib treatment for chronic myeloid leukemia.
title Long-term outcomes of imatinib treatment for chronic myeloid leukemia.
spellingShingle Long-term outcomes of imatinib treatment for chronic myeloid leukemia.
Hochhaus, Andreas
Leucèmia mieloide
Inhibidors enzimàtics
Hematologia
Myeloid leukemia
Enzyme inhibitors
Hematology
title_short Long-term outcomes of imatinib treatment for chronic myeloid leukemia.
title_full Long-term outcomes of imatinib treatment for chronic myeloid leukemia.
title_fullStr Long-term outcomes of imatinib treatment for chronic myeloid leukemia.
title_full_unstemmed Long-term outcomes of imatinib treatment for chronic myeloid leukemia.
title_sort Long-term outcomes of imatinib treatment for chronic myeloid leukemia.
dc.creator.none.fl_str_mv Hochhaus, Andreas
Larson, Richard A.
Guilhot, François
Radich, Jerald P.
Branford, Susan
Hughes, Timothy P.
Baccarani, Michele
Deininger, Michael W.
Cervantes Requena, F.
Fujihara, Satoko
Ortmann, Christine E.
Menssen, Hans D.
Kantarjian, Hagop M.
O'Brien, Stephen G.
Druker, Brian J.
author Hochhaus, Andreas
author_facet Hochhaus, Andreas
Larson, Richard A.
Guilhot, François
Radich, Jerald P.
Branford, Susan
Hughes, Timothy P.
Baccarani, Michele
Deininger, Michael W.
Cervantes Requena, F.
Fujihara, Satoko
Ortmann, Christine E.
Menssen, Hans D.
Kantarjian, Hagop M.
O'Brien, Stephen G.
Druker, Brian J.
author_role author
author2 Larson, Richard A.
Guilhot, François
Radich, Jerald P.
Branford, Susan
Hughes, Timothy P.
Baccarani, Michele
Deininger, Michael W.
Cervantes Requena, F.
Fujihara, Satoko
Ortmann, Christine E.
Menssen, Hans D.
Kantarjian, Hagop M.
O'Brien, Stephen G.
Druker, Brian J.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Leucèmia mieloide
Inhibidors enzimàtics
Hematologia
Myeloid leukemia
Enzyme inhibitors
Hematology
topic Leucèmia mieloide
Inhibidors enzimàtics
Hematologia
Myeloid leukemia
Enzyme inhibitors
Hematology
description BACKGROUND Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses on the basis of more than 10 years of follow-up in patients with CML who were treated with imatinib as initial therapy. METHODS In this open-label, multicenter trial with crossover design, we randomly assigned patients with newly diagnosed CML in the chronic phase to receive either imatinib or interferon alfa plus cytarabine. Long-term analyses included overall survival, response to treatment, and serious adverse events. RESULTS The median follow-up was 10.9 years. Given the high rate of crossover among patients who had been randomly assigned to receive interferon alfa plus cytarabine (65.6%) and the short duration of therapy before crossover in these patients (median, 0.8 years), the current analyses focused on patients who had been randomly assigned to receive imatinib. Among the patients in the imatinib group, the estimated overall survival rate at 10 years was 83.3%. Approximately half the patients (48.3%) who had been randomly assigned to imatinib completed study treatment with imatinib, and 82.8% had a complete cytogenetic response. Serious adverse events that were considered by the investigators to be related to imatinib were uncommon and most frequently occurred during the first year of treatment. CONCLUSIONS Almost 11 years of follow-up showed that the efficacy of imatinib persisted over time and that long-term administration of imatinib was not associated with unacceptable cumulative or late toxic effects. (Funded by Novartis Pharmaceuticals; IRIS ClinicalTrials.gov numbers, NCT00006343 and NCT00333840.)
publishDate 2017
dc.date.none.fl_str_mv 2017
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/108813
url https://hdl.handle.net/2445/108813
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1056/NEJMoa1609324
New England Journal of Medicine, 2017, vol. 376, num. 10, p. 917-927
https://doi.org/10.1056/NEJMoa1609324
dc.rights.none.fl_str_mv (c) Massachusetts Medical Society, 2017
info:eu-repo/semantics/openAccess
rights_invalid_str_mv (c) Massachusetts Medical Society, 2017
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Massachusetts Medical Society
publisher.none.fl_str_mv Massachusetts Medical Society
dc.source.none.fl_str_mv Articles publicats en revistes (Medicina)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869422460537929728
score 15.300719

Registros relacionados